Compare ARK Genomic Revolution ETF (ARKG) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs L3Harris Technologies Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while L3Harris Technologies Inc trades at $292.27 (market cap $54.17B). The key difference: L3Harris Technologies Inc pays a 1.72% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, L3Harris Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | LHX | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $378.48 |
52-Week Low | $23.09 | $259.55 |
Market Cap | — | $54.17B |
Enterprise Value | — | $64.94B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
LHX trades at $290.77, up 0.31% today, with a bearish technical signal but strong fundamentals. The company reported Q1 2026 EPS of $2.72, beating estimates, and maintains a 7.71% net income margin. Recent news includes a $84 million U.S. Army contract for NGC2 manpack systems (Business Wire, July 9, 2026). Cash flow from operations improved to $3.11B in 2025, while debt-to-asset ratio declined to 26.98%.
Outlook is positive with a consensus price target of $367.50, implying 26% upside, supported by 75% analyst buy ratings. Risks include execution delays in defense contracts and macroeconomic pressures. The stock offers value through earnings growth and dividend yield, but investors should monitor debt levels and competitive threats from new entrants like SpaceX.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
